Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS-mutated mCRC. Cardiff Oncology plans a registrational trial to compare ...

Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with ...

A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

Enhertu plus Perjeta received FDA priority review for first-line treatment of HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.

BTK inhibitors (BTKi) in mantle cell lymphoma (MCL) are examined by Tycel J. Phillips, MD, particularly as potential first-line therapy.

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

First-line treatment selection in follicular lymphoma is closely tied to tumor stage, disease burden, and patient-specific factors. Early-stage presentations may be managed with localized modalities, ...